Molbio Diagnostics IPO: A High-Risk Bet for Long-Term Investors

Molbio Diagnostics, a prominent player in molecular diagnostics, is gearing up for an initial public offering (IPO) aimed at raising a total of ₹940 crore. The company plans to secure ₹200 crore through a fresh issue of shares to bolster its capital expenditures, while an additional ₹740 crore will be generated through an offer for sale. This move will see the promoter group's stake reduced from 46.6% to 43%.

Global Reach and Revenue Streams

Established in 2000, Molbio Diagnostics operates six manufacturing facilities across India, providing diagnostic solutions to over 90 countries. The company's clientele includes government health programs, diagnostic labs, hospitals, and international healthcare organizations. A significant portion of its revenue, over 80%, is derived from government and international aid agencies.

The company's innovative 'Truenat' platform is designed to deliver accurate diagnostic results within an hour, specifically targeting resource-limited settings. Molbio offers molecular testing for more than 30 diseases through 43 diagnostic assays. Notably, nearly 74% of its revenue comes from the sale of test kits, with tuberculosis diagnostic kits alone contributing 70%.

Financial Growth and Performance

Molbio's financial performance has been robust, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. During the same period, net profit surged by 40.2% to ₹164.1 crore. The company's EBITDA rose by 33.2% to ₹328.2 crore, and its EBITDA margin improved from 22% in FY24 to 22.6% in FY26.

In FY26, Molbio reported a 41.7% year-on-year revenue increase, a 27.9% rise in EBITDA, and an 18.4% growth in net profit. These figures highlight the company's strong financial position and its potential for sustained growth.

Valuation and Market Comparison

Post-IPO, Molbio Diagnostics is expected to command a price-earnings (P/E) multiple of up to 57. Although the company lacks a directly comparable listed peer in India, other healthcare diagnostics and medical device firms, such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, have P/E multiples ranging from 54 to 81.

For investors with a high-risk appetite, Molbio's IPO offers a potential opportunity for long-term growth, particularly given the company's established market presence and innovative product offerings. However, the concentration of revenue from a limited number of top clients may pose a risk to consider.